YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Wall Street closed higher Friday as easing Treasury yields and lower oil prices supported equities, with investors continuing to monitor developments surrounding the Strait of Hormuz. The blue-chip Dow (DJI [https://seekingalpha.com/symbol…
[Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals.] jetcityimage * InnoCare Pharma (INCPF [https://seekingalpha.com/symbol/INCPF]) has entered a research collaboration and license agreement with Eli Lilly…
(RTTNews) - InnoCare Pharma Ltd (9969.HK), a commercial-stage biopharmaceutical company, announced that the Centre for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has granted priority review for its z…
As global markets grapple with concerns over AI disruption and mixed economic signals, Asian stocks have shown resilience, with some indices like Japan's Nikkei 225 experiencing notable gains. In this context, identifying undervalued stock…
As the Asian markets navigate a landscape marked by political shifts and economic adjustments, investors are keenly observing opportunities that may arise from these developments. In this context, identifying undervalued stocks becomes cru…
As global markets grapple with concerns over AI disruptions and economic shifts, Asian stocks have shown resilience, with Japan's indices surging on political stability and China's markets steadying ahead of the Lunar New Year. In this env…
InnoCare Pharma BEIJING, Feb. 12, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient h…
InnoCare Pharma BEIJING, Feb. 08, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug…
As global markets navigate a period of volatility marked by concerns over artificial intelligence and geopolitical tensions, investors are increasingly turning their attention to Asia's growth potential. In this environment, stocks with hi…
InnoCare Pharma BEIJING, Jan. 29, 2026 (GLOBE NEWSWIRE) -- JAMA Dermatology recently published the results of a Phase II study of novel TYK2 inhibitor soficitinib (ICP-332) in patients with moderate-to-severe atopic dermatitis (AD). The jo…
As the Asian markets navigate a complex landscape marked by mixed performances and cautious economic optimism, investors are increasingly on the lookout for opportunities in undervalued stocks. In this context, identifying stocks that offe…
(RTTNews) - InnoCare Pharma (INCPF) today announced that China's National Medical Products Administration has approved its IND application to initiate Phase II clinical trial of ICP-488, a novel TYK2 inhibitor, for the treatment of cutaneo…
InnoCare Pharma BEIJING, Dec. 23, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Inv…
InnoCare Pharma BEIJING, Dec. 17, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today the approval of the Inve…
Zenas BioPharma (ZBIO) is back in focus after partner InnoCare reported that orelabrutinib hit its primary endpoint in a Phase 2b lupus trial, and China has cleared a Phase 3 registrational study. See our latest analysis for Zenas BioPharm…
InnoCare Pharma (SEHK:9969) just cleared a key clinical hurdle, with BTK inhibitor orelabrutinib hitting its main goal in a phase IIb lupus trial and securing approval to move straight into a phase III registrational study in China. See ou…
Zenas BioPharma (ZBIO) said Monday that its partner InnoCare Pharma's phase 2b study evaluating orel PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Zenas BioPharma - Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE - - Zenas acquired the exclusive right to develop, manufacture and commercialize orelabrutinib in t…
InnoCare Pharma BEIJING, Dec. 14, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase IIb clin…
InnoCare Pharma BEIJING, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, announced today that its next-generation TRK inhibitor, zurletrectinib (ICP-723), has received appr…
InnoCare Pharma BEIJING, Dec. 09, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that over 20 studies of…
InnoCare Pharma BEIJING, Dec. 08, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that three studies of it…
InnoCare Pharma BEIJING, Nov. 27, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient h…
As global markets face volatility, particularly in the technology sector, Asian markets have shown resilience with Chinese indices reaching new highs amid easing trade tensions. In this environment, growth companies with high insider owner…
BEIJING, April 16, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE…
Amidst global economic uncertainties and inflation concerns, Asian markets have shown resilience, with business activity in the region continuing to expand despite external pressures. In such a volatile environment, growth companies with h…
As the Asian markets navigate a landscape marked by global economic uncertainty and inflation concerns, investors are keeping a close eye on high-growth tech stocks that have shown resilience amid broader market volatility. In this environ…
BEIJING, March 28, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in…
BEIJING, March 27, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the 2024 annual results as of 31 December 2024. Financial…
BEIJING, March 20, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in…
BEIJING, March 09, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the data of the novel TYK2 inhibito…
BEIJING, February 26, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the phase II results of orelabru…
BEIJING, February 17, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (…
BEIJING, January 20, 2025--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) today announced that the two companies, together with their joint venture, have jointly entered into an exclusive l…
BEIJING, December 09, 2024--(BUSINESS WIRE)--Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the ongoing 66th American Society of Hematology (ASH) Annual Meeting. Poster Presentation 1. Orelabrutinib in…
BEIJING, November 15, 2024--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed…